GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Institutional Ownership

Oculis Holding AG (FRA:CR5) Institutional Ownership : 1.57% (As of Jun. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oculis Holding AG's institutional ownership is 1.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oculis Holding AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oculis Holding AG's Float Percentage Of Total Shares Outstanding is 81.43%.


Oculis Holding AG Institutional Ownership Historical Data

The historical data trend for Oculis Holding AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Institutional Ownership Chart

Oculis Holding AG Historical Data

The historical data trend for Oculis Holding AG can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.02 2.47 4.31 2.47 2.48 2.37 2.21 2.16 1.76 1.57

Oculis Holding AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines